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Abstract
Hypothesis
We hypothesized that P wave terminal Force in the V1 lead (PTFV1) would be associated
with leukoaraiosis and subclinical infarcts, especially cortical infarcts, in a population-based,
multi-ethnic cohort.
Methods
PTFV1 was collected manually from baseline electrocardiograms of clinically stroke-free
Northern Manhattan Study participants. Investigators read brain MRIs for superficial
infarcts, deep infarcts, and white matter hyperintensity volume (WMHV). WMHV was
adjusted for head size and log transformed, achieving a normal distribution. Logistic regres-
sion models investigated the association of PTFV1 with cortical and with all subclinical
infarcts. Linear regression models examined logWMHV. Models were adjusted for demo-
graphics and risk factors.
Results
Among 1174 participants with PTFV1 measurements, the mean age at MRI was 70 ± 9
years. Participants were 14.4% white, 17.6% black, and 65.8% Hispanic. Mean PTFV1 was
3587.35 ± 2315.62 μV-ms. Of the 170 subclinical infarcts, 40 were cortical. PTFV1
5000 μV-ms was associated with WMHV in a fully adjusted model (mean difference in
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logWMHV 0.15, 95% confidence interval 0.01–0.28). PTFV1 exhibited a trend toward an
association with cortical infarcts (unadjusted OR per SD change logPTFV1 1.30, 95% CI
0.94–1.81), but not with all subclinical infarcts.
Conclusion
Electrocardiographic evidence of left atrial abnormality was associated with leukoaraiosis.
Introduction
Subclinical cerebrovascular disease (SCVD) includes subclinical infarcts and leukoaraiosis, or
white matter hyper-intensities often found in the peri-ventricular region but also in the sub-
cortical white matter. [1] SCVD has been found to be associated with cognitive decline [2, 3, 4]
and an increased incidence of ischemic stroke [2]. In addition, associations between SCVD
and vascular risk factors have been found. For example, age and hypertension were associated
with subclinical infarcts [5, 6]. Though the etiology of leukoaraiosis remains uncertain, it is
generally thought to represent a manifestation of small vessel vascular disease, and some stud-
ies have found an association between progression of leukoaraiosis and presence of vascular
risk factors such as current smoking, [7, 8] lower high density lipoprotein, [7] and hyperten-
sion [8], though not all studies have found each of these associations. [8, 9]
P wave terminal force in ECG lead V1 (PTFV1), a marker of “atrial cardiopathy” or left
atrial dysfunction [10], has been associated with clinical stroke, presumably through a cardi-
oembolic mechanism [11]. PTFV1 is thought to reflect atrial cardiopathy by indicating the
presence of electrical and anatomical changes in the left atrium. It has been suggested that
atrial cardiopathy could include a series of pathological changes in atria which would include
the electrical and anatomical changes reflected in PTFV1 but also changes to the atrial sub-
strate which could encourage thromboembolism [5, 12]. In addition, leukoaraiosis was found
to be associated with PTFV1 in a predominantly white population [13].
Though the effect of PTFV1 on SCVD has been investigated in a predominantly white pop-
ulation [13], it has not been well-studied in Hispanics and blacks. We hypothesized that
PTFV1 would be associated with an increased prevalence of subclinical infarcts, especially cor-




The Northern Manhattan Study (NOMAS) is a race/ethnically diverse population-based pro-
spective cohort of participants free of clinical stroke at baseline who were recruited between
1993 and 2001, as previously described [14]. After a baseline in-person examination, the 3,298
participants were followed annually by telephone to determine medical, socio-economic, and
other risk factors as well as the incidence of stroke and other vascular outcomes. Starting in
2003, NOMAS participants were invited to participate in an MRI substudy, which required
them to 1) be older than 50 years; 2) have no contraindications to MRI; and 3) be free of a clin-
ically recognized stroke. To increase the number of participants in the MRI study to 1,290, 199
household members of NOMAS participants were also invited to participate in the substudy.
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All participants gave informed consent. The study was approved by the Institutional Review
Boards at Columbia University Medical Center (CUMC) and the University of Miami.
Baseline evaluation of cohort
Participants underwent a thorough baseline examination including comprehensive medical
history, physical examination, and review of medical records. Study definitions for race–eth-
nicity, hypertension, diabetes, cardiac disease, and other risk factors have been described pre-
viously [15]. Trained bilingual research assistants performed interviews; study physicians
conducted physical and neurological examinations.
Measurement of P wave terminal force
The predictor, PTFV1, is the product of the depth (μV) and duration (ms) of the terminal por-
tion of the electrocardiogram (ECG) V1 lead’s biphasic P wave. PTFV1 was calculated from
paper ECGs taken at the time of initial enrollment for all participants in the MRI substudy, a
mean of 6.0 ± 3.4 years prior to MRI. The measurements of depth and duration were ascer-
tained manually with the use of a digital caliper by an investigator (MDH) who was blinded to
outcome. Measurements were then converted to μV and ms using the standard ECG calibra-
tion of 10 mm/mV and 25 mm/s. Prior studies have shown excellent intra-rater correlations
and moderate inter-rater correlations for manual measurements of P-wave morphology [16].
To confirm this in our cohort, as previously described, a second reader independently per-
formed blinded measurements of a random sample of 30 ECGs. Cases were excluded and
PTFV1 was coded as missing when inadequate ECG quality or the absence of P-waves due to
active AF prevented us from obtaining baseline PTFV1. Subjects with paroxysmal AF not
active on ECG remained in the study. Intraclass correlation coefficients for PTFV1 measure-
ments in the subset of 30 ECGs that were independently assessed by two investigators demon-
strated excellent intra-rater reliability (0.87; 95% CI, 0.79–0.92) and moderate inter-rater
reliability (0.69; 95% CI, 0.45–0.80), as previously reported [11].
Magnetic Resonance Imaging (MRI) outcomes
The primary outcomes were subclinical infarcts and white matter hyperintensities seen on
MRI. The MRI scans in NOMAS were performed according to specifications previously
described [5, 17]. Subclinical infarctions were defined as a hypointensity measuring greater
than 3 mm on FLAIR with no correlating signal void on T2; subclinical infarctions were also
categorized as superficial or deep [18].
As previously described [19], analyses for WMHV were performed using semi-automated
measurements of pixel distributions and mathematical modeling of pixel-intensity histograms
for cerebrospinal fluid and brain (white and gray matter) to identify the optimal pixel-intensity
threshold to distinguish cerebrospinal fluid from brain matter. Analyses were performed using
a custom-designed image analysis package (QUANTA 6.2 using a Sun Microsystems Ultra 5
workstation). WMHV, which conformed to the STRIVE criteria [20], was calculated after cor-
recting for total cranial volume to correct for differences in head size, and log-transformed to
achieve a normal distribution (log-WMHV) for analysis. All analyses were performed blinded
to participant identifying information and biomarker measurements.
Statistical analysis
Distributions of baseline characteristics were calculated. The predictor of interest, PTFV1 was
log transformed to achieve linearity and we used standard deviation (SD) increments as a
PTFV1 and silent vascular brain injury: NOMAS
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continuous measure. PTFV1 was also analyzed by quartiles and using a threshold used in prior
studies and also previously shown to be associated with risk of clinical stroke (>5000 μVms)
[21, 22, 23]. Logistic regression models were used to calculate odds ratios (OR) and 95% confi-
dence intervals (CI) for the association of PTFV1 with both all subclinical infarcts and with
superficial subclinical infarcts. Linear regression was used for the association of PTFV1 with
WMHV. Adjusted models accounted for demographics (race-ethnicity, age, sex, insurance sta-
tus, education) and risk factors (atrial fibrillation, congestive heart failure, diabetes, diastolic
and systolic blood pressure, smoking, high and low density lipoprotein cholesterol, glomerular
filtration rate). In a subsample in which left atrial diameter was available (n = 958), additional
analyses were performed further adjusting for left atrial diameter and left atrial enlargement.
All statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC).
Results
Description of the cohort
Among the 1174 participants with MRI scans and PTFV1 available, the mean age was 70 ± 9
years at the time of MRI, 40.3% were male, and 14.4% were white, 17.6% black, and 65.8% His-
panic. Most (68.0%) of participants had hypertension. MRIs were performed a mean of
6.0 ± 3.4 years after ECG. Subclinical infarcts were present in 170 participants (15.1%), and
were superficial in 40 (3.6%). PTFV1 had a mean of 3587.35 ± 2315.62 μV-ms and a median of
3063 μV-ms (interquartile range 2029.6–4559.2). The proportion of PTFV1>5000 μV-ms was
20%. Among the 958 participants with left atrial diameter available, the mean diameter was
36.0 ± 4.7 mm. According to categories used in previous studies, 80.3% had normal left atrial
size (women,38 mm; men,40 mm), and 26 had moderate (women, 43–46 mm; men, 47–
51 mm) or severe left atrial enlargement (women,47 mm; men,52 mm) [24]. Further base-
line characteristics are reported in Table 1.
Association of PTFV1 with subclinical infarction
There was a trend toward an association of PTFV1 with cortical infarcts (unadjusted OR per
SD change logPTFV1 1.30, 95% CI 0.93–1.81) but not with all subclinical infarcts (unadjusted
OR 1.00, 95% CI 0.85–1.18) in unadjusted models. In models adjusting for demographics and
all risk factors other than left atrial size, there was no longer a trend toward an association with
cortical infarcts (adjusted OR 1.09, 95% CI 0.76–1.57). Subclinical infarcts remained unassoci-
ated in adjusted models (adjusted OR 0.96, 95% CI 0.80–1.15). When compared to the first
quartile of PTFV1, the fourth quartile exhibited a trend toward an association with greater
prevalence of cortical infarcts in an unadjusted model (unadjusted OR 2.73, 95% CI 0.96–
7.76). The trend was attenuated when adjusted for demographics and risk factors (unadjusted
OR 1.86, 95% CI 0.61–5.71). Including left atrial size in the models among those with this mea-
sure available did not materially change the results. All results for subclinical infarcts are
reported in Table 2.
Association of PTFV1 with WMHV
PTFV1 >5000 μV-ms was associated with greater WMHV than PTFV1 <5000 μV-ms in an
unadjusted model (mean difference in logWMHV 0.28, 95% CI 0.14–0.42). The association
remained after adjusting for demographics and risk factors except left atrial diameter (mean
difference in logWMHV 0.15, 95% CI 0.01–0.28). Among the 958 participants with left atrial
size available, when left atrial diameter was included as a covariate, the association was no lon-
ger statistically significant (mean difference in logWMHV 0.14, 95% CI -0.02–0.29).
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When examined by quartiles, only the fourth quartile of PTFV1 (vs. the first quartile) was
associated with greater WMHV in the unadjusted model (mean difference in logWMHV 0.25,
95% CI 0.09–0.41). Similarly, PTFV1 as a continuous measure was associated with WMHV in
the unadjusted model (mean difference in logWMHV per SD of logPTFV1 0.08, 95% CI
0.026–0.14). The association was attenuated and lost significance when demographics and risk
factors were added to the final model (mean difference in logWMHV per SD of logPTFV1
0.02, 95% CI -0.03–0.07). Further adjusting for left atrial size did not change those results.
These results are summarized in Table 3.
Discussion
Electrocardiographic evidence of left atrial abnormality, in our cohort, was associated with
white matter hyperintensity volume, while the association with cortical infarcts seen in a previ-
ous study was not confirmed. Electrocardiographic abnormality reflected in the V1 lead
through P Wave Terminal Force (PTFV1) is thought to reflect structural or other abnormali-
ties of left atrial tissue, a condition that has been referred to as “atrial cardiopathy” [10]. Our
finding of an association of PTFV1 with small vessel disease provides evidence that electrocar-
diographic abnormalities reflecting structural or other abnormalities of left atrial tissue may be
associated with small vessel disease, cerebral hypoperfusion-related injury, or risk factors
shared between small vessel disease and left atrial abnormality. However, though previous
studies have suggested that atrial cardiopathy may be a source of emboli [11, 13], we did not
find a statistically significant association between PTFV1 and superficial infarcts, which we
assumed to be more likely embolic when compared to deep infarcts. Additionally, our results
Table 1. Baseline characteristics of the Northern Manhattan Study Magnetic Resonance Imaging cohort
(n = 1174).
Socio-demographic Characteristics Mean ± SD or n (%)




Non-Hispanic Black 207 (17.6)
Non-Hispanic White 169 (14.4)
Less than high school education 638 (54.3)
Medicaid or no insurance 555 (47.3)
Medical Characteristics
Smoking Status
Never used 559 (47.6)
Former smoker 429 (36.5)
Current user 186 (15.8)
Hypertension 798 (68.0)
Systolic blood pressure (mmHg) 139 ± 20
Diastolic blood pressures in mmHg 82.7 ± 10.6
Congestive heart failure 33 (2.81)
Low-density lipoprotein in mg/dl 128.0 ± 35.2
High-density lipoprotein in mg/dl 46.8 ± 14.7
Diabetes mellitus 227 (19.3)
Estimated Glomerular filtration rate in mL/min/1.73m2 80.1 ± 17.0
Left atrial diameter in mm 36.0±4.7
https://doi.org/10.1371/journal.pone.0203774.t001
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were attenuated in secondary analyses adjusting for left atrial size among those in whom the
measurement was available, suggesting that this electrocardiographic measure of P wave
abnormality may not be independent of echocardiographic measures and may reflect left atrial
size. These secondary analyses, however, may have been underpowered due to the limited
availability of left atrial diameter measures in the cohort.
The potential association between PTFV1 and WMHV is intriguing. This association was
also found in a prospective cohort study done within the Cardiovascular Health Study (CHS)
[13]. In the CHS study, PTFV1 measures were collected at baseline and repeat MRI scans five
years apart were interrogated for cortical infarcts and leukoaraiosis. The association found in
both studies could originate either from changes in cardiac function reflected in atrial cardiop-
athy or from risk factors shared by both atrial cardiopathy and leukoaraiosis. Atrial dysfunc-
tion reflected in PTFV11 could compromise perfusion to the brain sufficiently to damage
vulnerable areas of the brain. The possibility of decreased perfusion to vulnerable areas of the
brain in the setting of impaired cardiac function has previously been posited as a possible
















logPTFV1 per SD 1.00 (0.85–1.18) 0.96 (0.81–1.13) 0.96 (0.80–1.15) 0.94 (0.76–1.15)
PTFV1 Reference: First quartile
(<2029.6 μV-ms)
ref. ref. ref. ref.
Second quartile
(2029.6 μV-ms − 3063.0 μV-ms)
1.01 (0.63–1.61) 1.03 (0.64–1.68) 1.08 (0.65–1.79) 1.06 (0.60–1.87)
Third quartile
(3063.0 μV-ms − 4559.2 μV-ms)
1.05 (0.66–1.67) 1.06 (0.65–1.72) 1.04 (0.62–1.73) 1.07 (0.61–1.88)
Fourth quartile
(>4559.2 μV-ms)
1.14 (0.72–1.81) 1.01 (0.62–1.64) 1.04 (0.63–1.74) 0.87 (0.48–1.57)
PTFV1 Reference: <5000 μV-ms ref. ref. ref. ref.
>5000 μV-ms 1.19 (0.80–1.77) 1.00 (0.65–1.52) 1.02 (0.66–1.57) 0.91 (0.54–1.51)
Subclinical Cortical Infarcts
logPTFV1 per SD 1.30 (0.93–1.81) 1.19 (0.85–1.65) 1.09 (0.76–1.57) 1.03 (0.69–1.52)
PTFV1 Reference: First quartile
(<2029.6 μV-ms)
ref. ref. ref. ref.
Second quartile
(2029.6 μV-ms − 3063.0 μV-ms)
2.21 (0.76–6.44) 2.24 (0.75–6.62) 2.20 (0.71–6.75) 2.01 (0.64–6.37)
Third quartile
(3063.0 μV-ms − 4559.2 μV-ms)
2.29 (0.79–6.68) 2.20 (0.74–6.53) 1.74 (0.56–5.43) 1.43 (0.44–4.62)
Fourth quartile
(>4559.2 μV-ms)
2.73 (0.96–7.76) 2.27 (0.77–6.64) 1.86 (0.61–5.71) 1.30 (0.40–4.23)
PTFV1 Reference: <5000 μV-ms ref. ref. ref. ref.
>5000 μV-ms 1.55 (0.77–3.17) 1.22 (0.58–2.58) 1.10 (0.50–2.39) 0.84 (0.34–2.07)
Subclinical cortical infarcts exhibited trends to an association with log PTFV1, the fourth quartile of PTFV1, and a PTFV1 measurement above 5000 μV-ms which is a
threshold that has been used in previous studies. However, each of these trends were attenuated with adjustments and no significant associations were found.
Demographics include: race-ethnicity, age, sex, insurance status, and education
† Risk factors include: baseline atrial fibrillation, congestive heart failure, diabetes, diastolic and systolic blood pressure, smoking, low and high-density lipoprotein
cholesterol, and glomerular filtration rate
‡ Excluded subjects did not have left atrial size measurements
https://doi.org/10.1371/journal.pone.0203774.t002
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mechanism tying the association between leukoaraiosis and impaired ventricular function in
patients with and without congestive heart failure. [25, 26] In prior analyses from NOMAS, we
found that different left ventricular geometries and measures of left ventricular function more
sensitive than ejection fraction were associated with leukoaraiosis, even in patients with nor-
mal left ventricular ejection fraction. For example, of four left ventricular geometric patterns
(normal geometry, concentric remodeling, eccentric hypertrophy, and concentric hypertro-
phy), concentric hypertrophy was associated with leukoaraiosis, independent of ejection frac-
tion. [27] In another analysis, another measure of subclinical cardiac dysfunction, global
longitudinal strain (GLS), measured using speckle tracking on the echocardiogram, was associ-
ated with leukoaraiosis, even in patients with normal ejection fraction. Lower GLS was associ-
ated with greater white matter hyperintensity volume (adjusted β = 0.11, P<0.05). [28] In
patients without congestive heart failure, Shimizu et al [26] found an association between dia-
stolic dysfunction and leukoaraiosis.
Other studies, however, failed to confirm an association between cardiac output and leu-
koaraiosis [29], indicating that shared risk factors could be important contributors to the
development of both atrial cardiopathy and leukoaraiosis. For example, increased diastolic
blood pressure could contribute to leukoaraiosis and damage to the atrium as well. In fact,
within NOMAS, increased diastolic blood pressure has been associated with leukoaraiosis
[30]. Additionally, a prior study demonstrated the association between electrocardiographic
atrial abnormalities and hypertension [31]. These observations indicate that hypertension may
indeed be a shared risk factor for both atrial cardiopathy and leukoaraiosis. Though we con-
trolled for several known shared risk factors, leukoaraiosis is incompletely understood [32],
and we may not have controlled for shared risk factors that have not yet been discovered. In
addition, we cannot exclude the possibility of residual confounding due to misclassification or
measurement error. It is also possible that leukoaraiosis is due to cardiac emboli. Atrial















logPTFV1 per SD 0.082 (0.03–0.14) 0.038 (-0.014–0.089) 0.019 (-0.034–0.071) 0.018 (-0.042–0.078)
PTFV1 Reference: First quartile
(<2029.6 μV-ms)
ref. ref. ref. ref.
Second quartile
(2029.6 μVms − 3063.0 μV-ms)
0.096 (-0.06–0.26) 0.059 (-0.086–0.20) 0.036 (-0.11–0.18) 0.026 (-0.14–0.19)
Third quartile
(3063.0 μVms − 4559.2 μVms)
0.075 (-0.086–0.23) 0.037 (-0.11–0.18) 0.010 (-0.14–0.16) 0.046 (-0.11–0.21)
Fourth quartile
(>4559.2 μVms)
0.25 (0.088–0.41) 0.13 (-0.01–0.28) 0.085 (-0.064–0.23) 0.074 (-0.094–0.24)
PTFV1 Reference: <5000 μV-ms ref. ref. ref.
>5000 μV-ms 0.28 (0.14–0.42) 0.18 (0.050–0.31) 0.15 (0.014–0.28) 0.14 (-0.017–0.29)
In a model adjusting for demographics and risk factors except left atrial size, white Matter Hyperintensity Volume, a measure of leukoariosis, is associated with PTFV1
above 5000 μV-ms, a threshold used in previous studies. However, the association lost significance after adjusting for left atrial size.
 β is the average difference in logWMHV.
† Demographics include: race-ethnicity, age, sex, insurance status, and education
‡ Risk factors include: baseline atrial fibrillation, congestive heart failure, diabetes, diastolic and systolic blood pressure, smoking, low and high-density lipoprotein
cholesterol, and glomerular filtration rate
§ Excluded subjects did not have left atrial size measurements
https://doi.org/10.1371/journal.pone.0203774.t003
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fibrillation, the paradigmatic disorder causing cerebral emboli, can also be associated with
white matter lesions. [33] Further studies are needed to determine whether elevated PTFV1 is
associated with sufficient reduction in cardiac output to contribute to leukoaraiosis, and
whether any such changes are independent of conventional risk factors.
Given the results of previous studies, we expected to see an association between electrocar-
diographic abnormality and cortical infarcts. However, the lack of statistically significant
results is not surprising given the imperfect measure and small number of events. In a prior
case-cohort analysis conducted in our prospective NOMAS cohort, PTFV1 was more strongly
associated with cardioembolic and cryptogenic ischemic stroke subtypes than with ischemic
stroke in general [11]. This suggests that atrial cardiopathy as ascertained on ECG may be asso-
ciated with cardiac thromboembolism and thus ischemic stroke. In the analysis done on repeat
MRI scans within Cardiovascular Health Study (CHS), PTFV1 was associated with MRI-
defined incident infarcts, especially superficially located, embolic-appearing events [13]. The
results of the CHS study suggested again that electrocardiographic abnormality could reflect a
thromboembolic mechanism which may result in ischemic stroke. This present study did not
confirm the association between superficial infarcts and PTFV1 found in the CHS study,
though the trends were often in the expected direction. It is possible that no association was
found because non-differential misclassification in blinded manual measurements (“noise” or
imprecision in measurements”) biased the results toward the null and the small number of
superficial infarcts (n = 40) limited power. Further studies are warranted to confirm an associ-
ation between PTFV1 and subclinical cortical infarcts.
These results should be considered within the limitations of the study. First, measurement
of PTFV1 is subject to measurement error due to placement of the V1 lead of the ECG. Since
the recording varies depending where the lead is placed, variations in lead placement will
change the tracing, including the depth and width of the terminal P wave. However, this mea-
sure has been associated with outcomes in previous studies, and non-differential misclassifica-
tion is likely to bias results towards the null. In a prior study conducted in the Northern
Manhattan Study, moreover, which used the same ECGs, PTFV1 was associated with clinical
ischemic stroke [11]. Also, measurements for depth and duration for the calculation of PTFV1
were made manually. However, measurements were made blinded to outcome, so the results
were again likely biased toward the null and the true association is thus likely to be stronger.
Second, the small number of subclinical infarcts limited power. Third, it is possible that not all
participants with AF were identified since long-term heart-rhythm monitoring, which has
been shown to be sensitive for the detection of AF, was not conducted [34]. Also, only partici-
pants with paroxysmal AF could be included, because it is not possible to collect P wave mea-
surements during active AF. However, the models did adjust for known AF as a covariate and
other studies have shown that PTFV1 is associated with clinical ischemic stroke even after the
exclusion of participants with diagnosed AF [11].
This study also has strengths, including the race/ethnically diverse composition of the
cohort as well as the method of measurement used to quantify WMHV. The Northern Man-
hattan Study is a prospectively enrolled population-based cohort. The cohort includes blacks
and Hispanics, who are often understudied. In the MRI substudy of this cohort, volumetric
techniques were used to determine white matter disease on MRI rather than often imple-
mented semi-quantitative methods.
Conclusion
An electrocardiographic measure of left atrial cardiopathy is associated with leukoaraiosis.
This electrocardiographic measure may also be associated with subclinical cortical infarcts,
PTFV1 and silent vascular brain injury: NOMAS
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though our statistical power was not sufficient to show this. Future studies should be con-
ducted to replicate the results regarding both subclinical infarcts and leukoaraiosis in other
cohorts with different demographics, and these studies should attempt to distinguish any addi-
tive value of electrocardiographic measures beyond those provided by echocardiography.
Other studies should also investigate the mechanisms for the association between PTFV1 and
WMHV. Lastly, clinical trials aimed at preventing clinical strokes with PTFV1 as a predictor
may be warranted given the results of this and other studies. [11, 13]
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